vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and Virginia National Bankshares Corp (VABK). Click either name above to swap in a different company.

Virginia National Bankshares Corp is the larger business by last-quarter revenue ($15.0M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). Virginia National Bankshares Corp runs the higher net margin — 39.7% vs -1398.3%, a 1438.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 3.6%). Virginia National Bankshares Corp produced more free cash flow last quarter ($20.8M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 7.0%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

United Bankshares, Inc. is a bank holding company dual-headquartered in Charleston, West Virginia and Fairfax, Virginia with operations in West Virginia, Virginia, the District of Columbia, Maryland, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia in the United States. United Bankshares is the parent company of United Bank which comprises nearly 250 offices in eight states. In addition, UBSI is the parent company to subsidiaries George Mason Mortgage, United Brokerage, and Cre...

RNA vs VABK — Head-to-Head

Bigger by revenue
VABK
VABK
1.2× larger
VABK
$15.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+430.5% gap
RNA
434.0%
3.6%
VABK
Higher net margin
VABK
VABK
1438.0% more per $
VABK
39.7%
-1398.3%
RNA
More free cash flow
VABK
VABK
$177.6M more FCF
VABK
$20.8M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
7.0%
VABK

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
VABK
VABK
Revenue
$12.5M
$15.0M
Net Profit
$-174.4M
$6.0M
Gross Margin
Operating Margin
-1513.5%
50.5%
Net Margin
-1398.3%
39.7%
Revenue YoY
434.0%
3.6%
Net Profit YoY
-117.0%
30.6%
EPS (diluted)
$-1.27
$1.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
VABK
VABK
Q4 25
$15.0M
Q3 25
$12.5M
$14.4M
Q2 25
$3.8M
$14.1M
Q1 25
$1.6M
$14.1M
Q4 24
$3.0M
$14.5M
Q3 24
$2.3M
$13.5M
Q2 24
$2.0M
$12.9M
Q1 24
$3.5M
$13.1M
Net Profit
RNA
RNA
VABK
VABK
Q4 25
$6.0M
Q3 25
$-174.4M
$4.6M
Q2 25
$-157.3M
$4.2M
Q1 25
$-115.8M
$4.5M
Q4 24
$-102.3M
$4.6M
Q3 24
$-80.4M
$4.6M
Q2 24
$-70.8M
$4.2M
Q1 24
$-68.9M
$3.6M
Operating Margin
RNA
RNA
VABK
VABK
Q4 25
50.5%
Q3 25
-1513.5%
39.4%
Q2 25
-4448.7%
38.4%
Q1 25
-8360.9%
38.4%
Q4 24
-4069.6%
40.3%
Q3 24
-4200.9%
41.9%
Q2 24
-4040.4%
39.5%
Q1 24
-2178.6%
32.9%
Net Margin
RNA
RNA
VABK
VABK
Q4 25
39.7%
Q3 25
-1398.3%
31.7%
Q2 25
-4089.3%
30.0%
Q1 25
-7360.0%
31.9%
Q4 24
-3439.5%
31.4%
Q3 24
-3441.7%
34.1%
Q2 24
-3461.8%
32.3%
Q1 24
-1943.4%
27.8%
EPS (diluted)
RNA
RNA
VABK
VABK
Q4 25
$1.10
Q3 25
$-1.27
$0.84
Q2 25
$-1.21
$0.78
Q1 25
$-0.90
$0.83
Q4 24
$-0.80
$0.85
Q3 24
$-0.65
$0.85
Q2 24
$-0.65
$0.77
Q1 24
$-0.79
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
VABK
VABK
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$184.2M
Total Assets
$2.1B
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
VABK
VABK
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
RNA
RNA
VABK
VABK
Q4 25
$184.2M
Q3 25
$1.9B
$177.4M
Q2 25
$1.2B
$170.8M
Q1 25
$1.3B
$166.8M
Q4 24
$1.4B
$160.3M
Q3 24
$1.5B
$165.9M
Q2 24
$1.2B
$154.2M
Q1 24
$830.9M
$152.6M
Total Assets
RNA
RNA
VABK
VABK
Q4 25
$1.6B
Q3 25
$2.1B
$1.6B
Q2 25
$1.4B
$1.6B
Q1 25
$1.5B
$1.6B
Q4 24
$1.6B
$1.6B
Q3 24
$1.6B
$1.6B
Q2 24
$1.3B
$1.6B
Q1 24
$951.5M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
VABK
VABK
Operating Cash FlowLast quarter
$-156.2M
$21.3M
Free Cash FlowOCF − Capex
$-156.9M
$20.8M
FCF MarginFCF / Revenue
-1257.6%
138.2%
Capex IntensityCapex / Revenue
5.7%
3.9%
Cash ConversionOCF / Net Profit
3.58×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$35.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
VABK
VABK
Q4 25
$21.3M
Q3 25
$-156.2M
$6.0M
Q2 25
$-199.7M
$6.7M
Q1 25
$-124.8M
$2.1M
Q4 24
$-99.9M
$15.3M
Q3 24
$-65.6M
$15.2M
Q2 24
$-65.0M
$-6.4M
Q1 24
$-70.4M
$3.2M
Free Cash Flow
RNA
RNA
VABK
VABK
Q4 25
$20.8M
Q3 25
$-156.9M
$5.9M
Q2 25
$-203.0M
$6.7M
Q1 25
$-128.6M
$1.8M
Q4 24
$-103.8M
$14.6M
Q3 24
$-67.3M
$15.1M
Q2 24
$-65.5M
$-6.8M
Q1 24
$-71.3M
$3.1M
FCF Margin
RNA
RNA
VABK
VABK
Q4 25
138.2%
Q3 25
-1257.6%
41.0%
Q2 25
-5277.1%
47.6%
Q1 25
-8174.3%
13.0%
Q4 24
-3491.0%
100.4%
Q3 24
-2881.8%
111.7%
Q2 24
-3204.6%
-53.0%
Q1 24
-2012.3%
23.9%
Capex Intensity
RNA
RNA
VABK
VABK
Q4 25
3.9%
Q3 25
5.7%
0.5%
Q2 25
86.9%
0.2%
Q1 25
238.6%
1.8%
Q4 24
131.7%
5.1%
Q3 24
72.9%
0.9%
Q2 24
26.0%
3.1%
Q1 24
25.8%
0.2%
Cash Conversion
RNA
RNA
VABK
VABK
Q4 25
3.58×
Q3 25
1.31×
Q2 25
1.59×
Q1 25
0.47×
Q4 24
3.35×
Q3 24
3.30×
Q2 24
-1.54×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons